IJC Heart and Vasculature最新文献

{"title":"Outcomes of durable versus biodegradable polymer drug-eluting stents in patients with coronary artery disease","authors":"Christof Skos ,&nbsp;Jovan Rogozarski ,&nbsp;Al Medina Dizdarevic ,&nbsp;Gloria M.Steiner-Gager ,&nbsp;Marek Postula ,&nbsp;Ceren Eyileten ,&nbsp;Aurel Toma ,&nbsp;Walter S. Speidl ,&nbsp;Nika Skoro-Sajer ,&nbsp;Christian Gerges ,&nbsp;Irene M. Lang ,&nbsp;Jolanta M. Siller-Matula","doi":"10.1016/j.ijcha.2026.101882","DOIUrl":"10.1016/j.ijcha.2026.101882","url":null,"abstract":"<div><h3>Background</h3><div>Percutaneous coronary intervention (PCI) is among the most common cardiovascular procedures, but stents still pose risks of restenosis or thrombosis. Drug-eluting stents (DES) with polymer coatings have improved long-term outcomes.</div></div><div><h3>Aim</h3><div>This study evaluated whether the latest biodegradable polymer DES (BP-DES) offer improved safety over durable polymer DES (DP-DES).</div></div><div><h3>Methods</h3><div>Data were collected from a single-centre registry at the Medical University of Vienna, including patients who underwent PCI between 2015 and 2020. Patients were categorized by stent type and PCI indication (All Comer, CCS-PCI, ACS-PCI). The primary endpoint comprised of major adverse cardiac events (MACE), including target lesion revascularization (TLR), target vessel revascularization (TVR), stent thrombosis (ST), and all-cause death.</div></div><div><h3>Results</h3><div>2118 patients were eligible for further analysis. 1232 patients (58.2%) received a DP-DES. In the all-comer cohort, 5-year MACE rates were 12% for BP-DES vs 14.5% for DP-DES. Multivariate analysis showed no significant difference in MACE for the use of BP-DES (OR 0.941, 95% CI 0.734–1.207, p = 0.631). However, TLR rates were significantly lower in patients treated with BP-DES (3.4% vs 6.8%, OR 0.567, 95% CI 0.372–0.865, p = 0.008), mainly driven by lower rates of TLR within the ACS PCI cohort (1.5% vs 4.9%, OR 0.364, 95% CI 0.158–0.841, p = 0.018). In CCS PCI patients, MACE and TLR rates demonstrated no significant differences.</div></div><div><h3>Conclusion</h3><div>BP-DES and DP-DES show a similar long-term safety profile regarding MACE. BP-DES demonstrate a lower risk of TLR in the all-comer cohort, driven by reduced rates in ACS-PCI patients.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"63 ","pages":"Article 101882"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146190374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between treatment-induced changes in the Kansas City Cardiomyopathy Questionnaire and clinical outcomes in chronic heart failure: a trial-level meta-regression analysis","authors":"Hidekatsu Fukuta ,&nbsp;Toshihiko Goto","doi":"10.1016/j.ijcha.2026.101881","DOIUrl":"10.1016/j.ijcha.2026.101881","url":null,"abstract":"<div><h3>Background</h3><div>Patient-reported outcomes such as the Kansas City Cardiomyopathy Questionnaire (KCCQ) are increasingly recognized for their prognostic value. While the composite endpoint of cardiovascular death and heart failure (HF) hospitalization is the standard primary outcome in contemporary HF trials, the potential for KCCQ changes to serve as an intermediate endpoint for these clinical events requires further evaluation.</div></div><div><h3>Methods</h3><div>We conducted a trial-level meta-regression analysis of phase 3 randomized controlled trials (RCTs) evaluating pharmacological therapies for chronic HF that reported both changes in KCCQ and the primary composite endpoint of cardiovascular death and HF hospitalization. Weighted random-effects meta-regression models were used to assess the association between changes in KCCQ scores and treatment effects on clinical outcomes.</div></div><div><h3>Results</h3><div>Twelve phase 3 RCTs were included, comprising eight enrolling patients with HF with reduced ejection fraction and four enrolling those with preserved ejection fraction. Changes in KCCQ scores were significantly associated with treatment effects on the primary composite endpoint (regression coefficient [95% CI] = −0.0611 [−0.0930, −0.0292]; p = 0.001; I² = 2.2%), cardiovascular death (−0.0676 [−0.1099, −0.0254]; p = 0.004; I² = 0%), and HF hospitalization (−0.0700 [−0.1322, −0.0775]; p = 0.031; I² = 54%).</div></div><div><h3>Conclusion</h3><div>Treatment-induced changes in KCCQ scores are significantly correlated with clinical outcomes in phase 3 HF trials. These findings support KCCQ as a promising candidate intermediate endpoint that provides supportive evidence for the clinical benefit of HF therapies. However, our results remain hypothesis-generating, and further validation using individual patient data and cross-mechanism studies is warranted before KCCQ can be formally established as a regulatory surrogate endpoint.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"63 ","pages":"Article 101881"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146090739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Staging of Fabry cardiomyopathy in clinical practice: an algorithm proposal","authors":"Inês Fortuna ,&nbsp;Janete Santos ,&nbsp;Raquel Machado ,&nbsp;André Lobo ,&nbsp;Conceição Queirós ,&nbsp;Cristina Gavina ,&nbsp;Natália António ,&nbsp;Patrícia Rodrigues ,&nbsp;Ricardo Fontes-Carvalho ,&nbsp;Sofia Correia ,&nbsp;Giuseppe Limongelli ,&nbsp;Elisabete Martins","doi":"10.1016/j.ijcha.2025.101852","DOIUrl":"10.1016/j.ijcha.2025.101852","url":null,"abstract":"<div><h3>Purpose</h3><div>Fabry disease (FD) is characterized by hypertrophic cardiomyopathy and early diagnosis is essential, considering the response to enzyme replacement or chaperone therapies. Recently, a new clinical staging for Fabry cardiomyopathy suggested five stages (0A, 0B, IA, IB, II, III), where the imaging characterization of hypertrophy and fibrosis are critical key items. Our study aimed to evaluate the applicability of the recent proposal of Meucci et al. 2024 in patients with FD, considering the last imaging cardiac evaluations.</div></div><div><h3>Methods</h3><div>This retrospective observational study collected clinical data from patients diagnosed with FD. Staging system followed a hierarchical flowchart, staging patients based on LVEF, LGE, LV wall thickness, and other cardiac findings (symptoms, ECG/Echo/CMR abnormalities).</div></div><div><h3>Results</h3><div>We included 53 FD patients. As cardiac magnetic resonance and echocardiogram parameters are essential to complete staging, the algorithm was fully applied to 44 patients. Among these patients, the majority (29,5%) were in the non-hypertrophic stage 0. In hypertrophic stage I, 27,2% of patients were classified according to the maximum wall thickness. The hypertrophic fibrotic stage II included 29,5% of the patients. Patients in stage III (13,6%) presented diffuse myocardial fibrosis ≥ 3 LV segments and/or impaired systolic function (LVEF &lt; 50%).</div></div><div><h3>Conclusion</h3><div>The staging scheme allows us to classify different stages of FD cardiomyopathy. Most patients were in early disease stages, probably related to the diagnosis in the context of familial screening. The stepwise algorithm proposal helped apply the staging in clinical practice; however, it must be validated in more extensive and prospective studies.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"63 ","pages":"Article 101852"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146174505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of pullback measurement on treatment decision in significant coronary artery disease: Insights from a retrospective multicentric study","authors":"Roberto Bova ,&nbsp;Matteo Betti ,&nbsp;Samuel Heuts ,&nbsp;Pieter A. Vriesendorp ,&nbsp;Alexander J.J. Ijsselmuiden ,&nbsp;Saman Rasoul ,&nbsp;Mustafa Ilhan ,&nbsp;Jindra Vainer ,&nbsp;Ralph A.L.J. Theunissen ,&nbsp;Leo F. Veenstra ,&nbsp;Patty Winkler ,&nbsp;Mera Stein ,&nbsp;Alexander Ruiters ,&nbsp;Daniek P.J. Slegers ,&nbsp;Arnoud W.J. van ’t Hof ,&nbsp;Arpad Lux","doi":"10.1016/j.ijcha.2026.101887","DOIUrl":"10.1016/j.ijcha.2026.101887","url":null,"abstract":"<div><h3>Background</h3><div>Optimal management of coronary artery disease (CAD) requires tailoring treatment strategies to lesion characteristics. Intracoronary pullback enables hemodynamic mapping of coronary lesions, potentially improving therapeutic decision-making, particularly in distinguishing focal from diffuse disease.</div></div><div><h3>Objectives</h3><div>To evaluate how pullback measurement influences overall treatment strategy—optimal medical therapy (OMT), percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG)—in patients with significant CAD.</div></div><div><h3>Methods</h3><div>We conducted a retrospective, multicenter cohort study including 842 patients with stable angina, unstable angina, or non-ST-elevation myocardial infarction (NSTEMI) and functionally significant left anterior descending artery (LAD) disease. Patients were stratified into two groups: one group (PB group, n = 561) had pullback measurement, and the other (Conventional group, n = 281) not. Outcomes included treatment strategy, major adverse cardiovascular events (MACE), and all-cause mortality at 1 year.</div></div><div><h3>Results</h3><div>Pullback led to more Heart Team discussions (66.3% vs. 58.7%; p = 0.033), greater adoption of OMT (51.5% vs. 40.9%; p = 0.004), and lower PCI rates (27.1% vs. 36.3%; p = 0.007). CABG rates remained unaffected. Pullback independently increased the odds of OMT and reduced the odds of PCI (OR = 0.58, p = 0.003), while three-vessel disease strongly predicted CABG (OR = 2.51; p &lt; 0.001). At 1 year, the PB group had higher mortality (4.3% vs. 1.1%, p = 0.013), but similar MACE compared to the Conventional group. However, clinical outcomes did not differ between treatment groups.</div></div><div><h3>Conclusions</h3><div>Intracoronary pullback favours a conservative treatment strategy. MACE rates are not increased at 1 year.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"63 ","pages":"Article 101887"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146190375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxygen therapy enhances the systemic inflammatory response in a human model of experimental inflammation","authors":"P. Tornvall ,&nbsp;P. Svensson ,&nbsp;J. Alfredsson ,&nbsp;L. Jonasson ,&nbsp;L. Nilsson ,&nbsp;R. Hofmann ,&nbsp;SK. Merid","doi":"10.1016/j.ijcha.2025.101846","DOIUrl":"10.1016/j.ijcha.2025.101846","url":null,"abstract":"<div><h3>Introduction</h3><div>Oxygen therapy does not benefit normoxemic patients with suspected myocardial infarction and may instead enhance the inflammatory response triggered by the tissue necrosis caused by the myocardial infarction. In the present study, we tested the hypothesis that oxygen therapy aggravates systemic inflammation in normoxemic healthy individuals in a human model of experimental inflammation.</div></div><div><h3>Methods</h3><div>Proteomic and gene expression data from healthy subjects vaccinated against Salmonella Typhii and exposed to oxygen therapy or ambient air were investigated. A multi-omics approach with factor analysis to identify common sources of variation in the systemic inflammatory response associated with oxygen exposure was used.</div></div><div><h3>Results</h3><div>Oxygen therapy showed a statistically nominal tendency toward aggravation determined by ELISA (IL-6) and proximity extension assay (IL-8). The factor analysis revealed a pro-inflammatory feature that included increases in (CXCL 6, 10 and 11) with decreased small nucleolar RNA.</div></div><div><h3>Conclusion</h3><div>The results indicate that oxygen therapy enhances experimental systemic inflammation. The mechanism is not clear but future studies should address small nucleolar RNA.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"62 ","pages":"Article 101846"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145616294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alcohol use disorder and use of rhythm control therapies in patients with atrial fibrillation: A nationwide cohort study","authors":"Miika Vanhanen ,&nbsp;Jussi Jaakkola ,&nbsp;Juhani K.E. Airaksinen ,&nbsp;Olli Halminen ,&nbsp;Jukka Putaala ,&nbsp;Pirjo Mustonen ,&nbsp;Jari Haukka ,&nbsp;Juha Hartikainen ,&nbsp;Alex Luojus ,&nbsp;Mikko Niemi ,&nbsp;Miika Linna ,&nbsp;Mika Lehto ,&nbsp;Konsta Teppo","doi":"10.1016/j.ijcha.2025.101854","DOIUrl":"10.1016/j.ijcha.2025.101854","url":null,"abstract":"<div><h3>Objective</h3><div>Patients with alcohol use disorder (AUD) often receive inferior treatment for somatic comorbidities. We aimed to examine whether AUD is associated with disparities in the use of antiarrhythmic therapies (AAT) for rhythm control in atrial fibrillation (AF) patients, using a nationwide registry.</div></div><div><h3>Methods</h3><div>The Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) registry includes all 229,565 patients with incident AF diagnosed in Finland between 2007 and 2018, identified from comprehensive national healthcare registries. The primary outcome was initiation of rhythm control therapies, including antiarrhythmic drugs, cardioversion, and catheter ablation, in patients with and without AUD.</div></div><div><h3>Results</h3><div>The mean age was 72.7 years, 50 % were female and 4.7 % had AUD. Rhythm control was initiated less often in patients with AUD compared to those without (13.6 % vs. 21.8 %, p &lt; 0.001). After adjustment for comorbidities and socioeconomic status, AUD remained associated with lower use of rhythm control therapies (HR 0.65; 95 % CI 0.62–0.69). This disparity was consistent across all modalities of rhythm control (antiarrhythmic drugs, cardioversion and catheter ablation). While no significant interaction was observed with sex or age, income modified the association (p &lt; 0.001), with the lowest income tertile showing the greatest disparity (HR 0.37; 95 % CI 0.32–0.42).</div></div><div><h3>Conclusions</h3><div>AUD is independently associated with markedly lower use of rhythm control therapies in AF patients. These disparities are most pronounced among socioeconomically disadvantaged individuals, highlighting the need for targeted interventions to ensure equitable treatment access.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"62 ","pages":"Article 101854"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145789550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic anticipation and cardiac conduction abnormalities in myotonic dystrophy type 1: implications for early stratification from a multicenter registry","authors":"Rebeca Lorca ,&nbsp;Alberto Alen ,&nbsp;Carlos Moliner-Abós ,&nbsp;Fernando de Frutos ,&nbsp;Néstor Báez-Ferrer ,&nbsp;María Luisa Peña-Peña ,&nbsp;Eduardo Villacorta ,&nbsp;Tomas Ripoll-Vera ,&nbsp;Esther Zorio ,&nbsp;Aaron Martínez-Gimeno ,&nbsp;José Bermúdez-Jiménez ,&nbsp;Javier Limeres ,&nbsp;Coloma Tiron ,&nbsp;José M. Larrañaga-Moreira ,&nbsp;Eva Cabrera-Romero ,&nbsp;Pablo García-Pavía ,&nbsp;María Angeles Espinosa ,&nbsp;Jesús Piqueras ,&nbsp;Soledad García-Hernández ,&nbsp;Julián Palomino-Doza ,&nbsp;Carmen Muñoz","doi":"10.1016/j.ijcha.2025.101851","DOIUrl":"10.1016/j.ijcha.2025.101851","url":null,"abstract":"<div><h3>Background</h3><div>DM1 is an autosomal dominant disorder caused by unstable CTG repeats that expand over lifetime and in successive generations, contributing to genetic anticipation. Cardiac conduction abnormalities (CCAs) are a major source of morbidity and premature death in DM1, yet the influence of age at diagnosis, generation, and CTG repeat length on the timing and progression of cardiac involvement remains poorly defined.</div></div><div><h3>Method</h3><div>This multicentric retrospective study included 549 adult DM1 patients from 16 hospitals in Spain. The primary composite endpoint comprised significant CCAs, device implantation, malignant ventricular arrhythmias and cardiac syncope. Patients were stratified by age‑at‑diagnosis (&lt;40, 40–59, and ≥60 years); birth generation (1920–1965, 1966–1990, 1991–2015), and CTG repeat length (&lt;100, 100–599, and ≥600).</div></div><div><h3>Results</h3><div>During follow‑up, 33.1 % of patients experienced the primary endpoint. This risk was 4.7‑fold higher in the youngest group versus the oldest group (HR 4.70; p &lt; 0.001); 35‑fold higher in the 3rd generation versus the 1st and increased progressively with longer CTG expansions. Device implantation rates were likewise higher in younger patients, later generations, and those with larger repeat lengths.</div></div><div><h3>Conclusion</h3><div>The results demonstrate a striking anticipation pattern in the cardiac phenotype of DM1, with progressively earlier and more severe electrical disease paralleling CTG expansion across generations. Incorporating age at diagnosis, generational cohort, and genetic repeat burden into clinical assessment may enhance risk stratification and enable earlier, targeted rhythm surveillance and device therapy to prevent sudden cardiac death in DM1.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"62 ","pages":"Article 101851"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute pulmonary vasoreactivity: a simple test revisited in the contemporary era − a narrative review","authors":"Juan C Grignola ,&nbsp;Pedro Trujillo ,&nbsp;Julio Sandoval ,&nbsp;Enric Domingo","doi":"10.1016/j.ijcha.2025.101847","DOIUrl":"10.1016/j.ijcha.2025.101847","url":null,"abstract":"<div><div>The acute vasodilator challenge during right heart catheterization (RHC) provides a deeper understanding of the pulmonary circulation by assessing vasoreactivity. The current criteria for a positive acute vasoreactivity test (AVT) are simplified to steady-state metrics, based on cutoff points derived from expert opinion. A positive AVT identifies a specific, but very rare, PH phenotype that may respond long-term to calcium-channel blockers. Growing evidence supports updating the role and criteria of AVT in pulmonary arterial hypertension, broadening its use to other PH groups, and potentially offering new insights for predicting risk and/or treatment outcomes.</div><div>This study aims to revisit the uses, criteria, and goals of AVT in patients with PH beyond group 1 and to propose a new approach for phenotyping the pulmonary vascular response to the acute vasodilator challenge during diagnostic RHC. We propose a continuous multi-parameter criterion to evaluate the entire right ventricular afterload during AVT, such as the pulmonary vascular resistance-pulmonary arterial capacitance curve and alpha distensibility coefficient. AVT could assess the residual vasoreactive reserve of the pulmonary circulation as a provocative test for predicting risk outcomes and/or treatment responses.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"62 ","pages":"Article 101847"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145684636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of quantitative cardiovascular MRI and late gadolinium enhancement patterns in differentiating late-onset Anderson-Fabry disease (c.640–801G > A) from hypertrophic cardiomyopathy: a case-control study","authors":"Yilin Xu ,&nbsp;Rui Chen ,&nbsp;Xinglu Li ,&nbsp;Huihua Lin ,&nbsp;Lirong Lin ,&nbsp;Lihong Lu ,&nbsp;XiaoMin Dai ,&nbsp;Yingbin Yu ,&nbsp;YuYing Lin ,&nbsp;Lei Yin ,&nbsp;Mingping Ma","doi":"10.1016/j.ijcha.2026.101869","DOIUrl":"10.1016/j.ijcha.2026.101869","url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate the utility of cardiovascular magnetic resonance imaging (CMR) in distinguishing Anderson-Fabry disease (AFD) harboring the c.640–801G &gt; A mutation from hypertrophic cardiomyopathy (HCM).</div></div><div><h3>Methods and results</h3><div>We enrolled 30 AFD patients, 30 age- and sex-matched HCM patients, and 30 healthy controls (HC). All participants underwent CMR (3.0 T). Left ventricular hypertrophy (LVH) prevalence was high in both AFD and HCM groups (P = 0.12). AFD patients exhibited significantly greater left ventricular lateral wall thickness compared to both HCM and HC (P &lt; 0.001), and a significantly lower interventricular septal to lateral wall thickness ratio (IVS/LW) than HCM (P &lt; 0.001). Late gadolinium enhancement (LGE) was significantly more frequent in the basal inferolateral and apical segments in AFD compared to HCM (P &lt; 0.001 and P = 0.039, respectively). Native T1 values were significantly lower in AFD than HCM in the global LV, septal LV, and within LGE regions (all P &lt; 0.001). Compared to HC, AFD patients had significantly lower septal native T1 (P &lt; 0.001), but comparable global LV native T1 (P = 0.155). Native T1 cut-offs effectively discriminated AFD from HCM: septal native T1 ≤ 1247 ms, global native T1 ≤ 1256 ms, and LGE region native T1 ≤ 1334 ms. Septal native T1 demonstrated the strongest discriminatory capacity.</div></div><div><h3>Conclusion</h3><div>CMR effectively differentiates AFD patients with the c.640–801G &gt; A mutation from HCM. Key discriminators include lower native T1 values (Caution against pseudo-normalization), higher prevalence of basal inferolateral LGE, and more symmetric LVH in AFD.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"62 ","pages":"Article 101869"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of liver shear wave elastography after transcatheter aortic valve implantation in severe aortic stenosis","authors":"Yutaro Sato ,&nbsp;Akihiko Sato ,&nbsp;Kazuya Sakamoto ,&nbsp;Yuuki Muto ,&nbsp;Yu Sato ,&nbsp;Tetsuro Yokokawa ,&nbsp;Takeshi Shimizu ,&nbsp;Tomofumi Misaka ,&nbsp;Takashi Kaneshiro ,&nbsp;Masayoshi Oikawa ,&nbsp;Atsushi Kobayashi ,&nbsp;Akiomi Yoshihisa ,&nbsp;Yasuchika Takeishi","doi":"10.1016/j.ijcha.2025.101864","DOIUrl":"10.1016/j.ijcha.2025.101864","url":null,"abstract":"<div><h3>Background</h3><div>Shear wave elastography (SWE) is a noninvasive ultrasound technique that quantifies liver stiffness. Previous studies have suggested that liver SWE can serve as an indirect marker of hepatic congestion. However, it remains unclear whether liver SWE measured after transcatheter aortic valve implantation (TAVI) is associated with clinical outcomes.</div></div><div><h3>Methods</h3><div>A total of 127 consecutive patients with severe aortic stenosis who underwent TAVI and had liver SWE measured using abdominal ultrasonography at discharge were enrolled. Liver SWE was obtained from the right hepatic lobe via an intercostal approach. Patients were stratified by the median liver SWE value (1.36 m/s): low-SWE group (&lt; 1.36 m/s; <em>n</em> = 59) and high-SWE group (≥ 1.36 m/s; <em>n</em> = 68). The primary endpoint was a composite of all-cause death and heart failure (HF) rehospitalization.</div></div><div><h3>Results</h3><div>All 127 patients were followed for 24 months, during which 21 (16.5 %) experienced the primary endpoint. Kaplan–Meier analysis showed a higher cumulative incidence of the primary endpoint in the high-SWE group than in the low-SWE group (log-rank <em>P</em> = 0.019). In Cox proportional hazards models adjusted using inverse probability of treatment weighting, high liver SWE was independently associated with an increased risk of the primary endpoint (hazard ratio 3.66; 95 % confidence interval 1.30–10.32; <em>P</em> = 0.014).</div></div><div><h3>Conclusion</h3><div>High liver SWE after TAVI was independently associated with an increased 24-month risk of all-cause death and HF rehospitalization.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"62 ","pages":"Article 101864"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}